Exkivity Received Accelerated Clearance from the UK’s Medicines and Healthcare Products Regulatory Agency
The National Health Service England said on Friday that Takeda’s Exkivity (mobocertinib) will be made available to patients with metastatic non-small cell lung cancer who have EGFR exon 20 insertion mutations in their tumours and have already taken chemotherapy.
After brokering a deal between the National Institute for Health and Care Excellence (NICE) and Takeda, NHS England announced the medicine will be available to patients in the nation “within weeks.”
Exkivity received accelerated clearance from the UK’s Medicines and Healthcare Products Regulatory Agency in January, paving the way for the merger. Exkivity decreased tumours in 28 percent of 114 patients in a Phase I/II study, according to the MHRA. The median response time was 17.5 months, and the median progression-fee survival time was 7.3 months.
The MHRA obtained this information through Project Orbis, a global collaboration involving health regulators in the United Kingdom, the United States, Australia, and other countries aimed at accelerating access to novel medications. Exkivity is the fourth precision oncology treatment examined under Project Orbis that the government has been able to fast track access to, following Genentech’s Tecentriq (atezolizumab),AstraZeneca’s Tagrisso (osimertinib),and Amgen’s Lumykras (sotorasib), according to NHS England.
Last September, the FDA authorisedExkivity for the same indication. Takeda reportedly released Exkivity in the United States for a wholesale purchase cost of $25,000 for a month’s supply of oral tablet, according to the NHS.
Takeda has agreed to make Exkivity available to patients on a budget-neutral basis until NICE completes its cost-effectiveness assessment as part of the early-access agreement in England.
Helen Knight said they are glad that they’ve been able to achieve an agreement with Takeda, the MHRA, and NHS England to make mobocertinib accessible for individuals with this form of lung cancer while they continue the review,said, programme director at NICE’s Center for (HTE)Health Technology Evaluation.
According to NHS England, NSCLC patients in England will be the first in Europe to receive the medicine as a result of this agreement. Patients suffering from advanced NSCLC who have EGFR exon 20 insertion mutations are typically young, nonsmokers, and have tumours that are difficult to remove surgically. Exkivity will be available to about 100 advanced NSCLC patients per year.
Exkivity is the first oral treatment for advanced non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) exon 20 insertion mutations, a kind of genetic abnormality. The FDA prioritisedExkivity’s approval.
View Latest News Published by TTP
Follow Us: TWITTER